EDISON, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company
focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the 2017
Biotechnology Innovation Organization (BIO) International Convention being held June 19 - 22, 2017 in San Diego,
California.
James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview of the Company's business during a live
presentation and is available to meet with investors and other companies who are registered to attend the conference.
Interested parties may contact ContraVir through the BIO One-on-One Partnering™ system.
|
Event: |
|
BIO
International Conference |
|
Date: |
|
Wednesday, June 21, 2017 |
|
Time: |
|
10:45 AM (Pacific Time) |
|
Location: |
|
Theater 3 |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a
specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase 2a, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target effects caused by high levels of circulating TFV. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against
HBV. ContraVir is also developing Valnivudine™, an orally available nucleoside analogue prodrug; Valnivudine™ is currently in Phase
3 for the treatment of herpes zoster. In addition to direct antiviral activity, Phase 2 data suggest that Valnivudine™ has the
potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). For more
information visit www.contravir.com.
For further information, please contact: Sharen Pyatetskaya Director of Investor Relations sp@contravir.com; (732) 902-4028
